← First Tracks Biotherapeutics, Inc. (TRAX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
First Tracks Biotherapeutics, Inc. (TRAX)
Pharmaceutical Preparations · market cap $1.4B
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
0
programs
Upcoming events
8
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-01-01Phase 3imp 4/10
- 2027-02-28Phase 3imp 8/10
- 2027-04-14PDUFAimp 8/10
- 2027-05-29 (est.)PDUFA · MOGENRY®imp 9/10
- 2027-06-17 (est.)PDUFA · Cemdisiranimp 8/10
- 2027-09-04 (est.)PDUFA · MOGENRYimp 8/10
- 2027-09-25 (est.)PDUFA · tabelecleucelimp 8/10
Pipeline
No pipeline data.
Price & technical context
3-month
+68.4%
6-month
—
12-month
—
52-wk range
$15.32–$47.92
vs 50-day MA
-18.5%
vs 200-day MA
—
Realized vol
119.9%
Max drawdown
-39.7%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TRAX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.